Migraine without aura. Migraine without aura [common migraine]
Conditions
Interventions
Patients will be divided into four groups, according to stratified randomization method: 1.The group receiving ubiquinone (sauna medicine in Parseh, Iran) (100 mg three times daily) and nanocorcomin (
Treatment - Drugs
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 20 to 45 years old; Patients with episodic migraine; Migraine Diagnosis by International Headache Society Criteria as Applied by a Neurologist; No nutritional supplement or professional sports activities four weeks before intervention; People who are willing to cooperate voluntarily. Exclusion criteria: Kidney disease; liver disease; pancreatitis; diabetes; cancer; thyroid disorders and inflammatory diseases based on medical history; Malnutrition (body mass index less than 18.5) and obesity (body mass index greater than 30); Vitamin supplementation during the three months before intervention; Pregnancy; Alcohol consumption over the past six months; smoking; Patients with history of cardiovascular disease; Taking anti-inflammatory drugs or supplements such as ubiquinone and curcumin; Allergic reaction to the ubiquinone and/or Curcumin supplement; Lack of patient collaboration; Any significant changes in diet and routine life.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of headache attacks. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Questionnaires to assess disease progression.;Duration of the headache. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Questionnaires to assess disease progression.;Headache severity. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Questionnaires to assess disease progression. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of calcitonin gene-related peptide. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable.;Serum levels of homocysteine. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable.;Oxidative stress profile. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable.;Activity of antioxidant enzymes catalase, superoxide dismutase, glutathione peroxidase. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable.;Gene expression of anti-oxidant enzymes catalase, superoxide dismutase, glutathione peroxidase in peripheral blood mononuclear cells. Timepoint: Before intervention and 8 weeks after intervention. Method of measurement: Using appropriate laboratory methods for each variable. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMohammad Prohan
Tehran University of Medical Sciences
Outcome results
None listed